BioNTech SE Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
BioNTech SE (BNTX) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of EUR 89.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-10
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month as first filed |
|---|---|---|
| 2025-12-31 | 89.00M EUR 20-F · filed 2026-03-10 | |
| 2024-12-31 | 74.90M EUR 20-F · filed 2026-03-10 | 85.00M EUR 20-F · filed 2025-03-10 |
| 2023-12-31 | 44.10M EUR 20-F · filed 2026-03-10 | |
| 2022-12-31 | 46.50M EUR 20-F · filed 2025-03-10 | |
| 2021-12-31 | 61.00M EUR 20-F · filed 2024-03-20 | |
| 2020-12-31 | 32.10M EUR 20-F · filed 2023-03-27 | |
| 2019-12-31 | 30.20M EUR 20-F/A · filed 2022-10-26 |